Ann: Quarterly Activities Report, page-105

from the quarterly some announcements we should expect soon, or will be updated in the annual report due in the next couple of weeks

In the March quarter AnteoTech reported that it expected results of electrochemical testing of our generation 1 silicon composite by Collaborator 1 during July. We have arranged an update on progress to be discussed with Collaborator 1 in the next 2 weeks.

A shipment of AnteoTech cross-linker binder additive was sent to Collaborator 5 in June and they have acknowledged receipt. Testing is underway and we expect results in 1 to 2 months.

Assay Development & Conjugation Services – Serum Institute of India, Work will begin on the feasibility in August.

Merck - During May we agreed pricing with Merck for the OEM development of the 300nm AnteoBind activated Europium particle. In a separate meeting we tabled contracts which Merck are now assessing.

ISO 13485 We expect certification to be awarded in August.

Prompt progression through development phases of the COVID-19 rapid test toward design validation and laboratory-based COVID-19 sample evaluation and regulatory approval.

also have Charlie's Luminex webinar on Wednesday.